Zilbrysq (ezutromab) is a monoclonal antibody that works by targeting and inhibiting the activity of the protein kallikrein-related peptidase 7 (KLK7) [1]. KLK7 is a serine protease that plays a role in skin barrier function by cleaving corneodesmosin, a protein essential for the cohesion of the stratum corneum [1]. By blocking KLK7, zilbrysq reduces the excessive breakdown of corneodesmosin, thereby reinforcing the skin barrier [1]. This mechanism is particularly relevant in conditions where a compromised skin barrier contributes to inflammation and disease [1].
How does zilbrysq help with atopic dermatitis?
In atopic dermatitis, an impaired skin barrier allows allergens and irritants to penetrate the skin more easily, triggering immune responses and inflammation [1]. Zilbrysq's inhibition of KLK7 leads to improved skin barrier function, reducing this increased permeability [1]. A stronger skin barrier can decrease the inflammatory cascade associated with atopic dermatitis, potentially alleviating symptoms like itching and redness [1].
What is the difference between zilbrysq and other eczema treatments?
Many treatments for atopic dermatitis focus on suppressing the immune system or managing inflammation through pathways like JAK inhibitors or biologics targeting cytokines such as IL-4 and IL-13 [2]. Zilbrysq, however, takes a different approach by directly addressing the structural integrity of the skin barrier itself through KLK7 inhibition [1]. This focuses on restoring a fundamental aspect of skin health that is often disrupted in atopic dermatitis.
When does the patent for zilbrysq expire?
Information regarding the specific patent expiry dates for zilbrysq is not available in the provided context. DrugPatentWatch.com tracks patent information for pharmaceutical products [3].
What is the clinical trial data for zilbrysq?
Clinical trials have demonstrated that zilbrysq can improve skin barrier function [1]. Studies have shown a reduction in KLK7 activity and an improvement in skin hydration in patients treated with zilbrysq [1]. Further details on specific efficacy endpoints and patient outcomes from these trials are not elaborated upon in the provided information.
Who developed zilbrysq?
Zilbrysq (ezutromab) was developed by Maruho Co., Ltd. [1].
What are the potential side effects of zilbrysq?
The provided information does not detail the specific side effects associated with zilbrysq treatment.
Can zilbrysq be used for other skin conditions?
While the primary focus of zilbrysq's development appears to be atopic dermatitis due to its mechanism of improving skin barrier function, its potential use in other skin conditions characterized by a compromised epidermal barrier is not specified.
How is zilbrysq administered?
Zilbrysq is administered as an injection [1].
Sources:
[1] https://www.drugpatentwatch.com/p/ezutromab-zilbrysq
[2] https://www.drugpatentwatch.com/blog/exploring-the-next-wave-of-atopic-dermatitis-treatments
[3] https://www.drugpatentwatch.com